In the described Roundup regulatory case, which order of assessment is correct?

In the described Roundup regulatory case, which order of assessment is correct?

• A. IARC labeled the substance a probable human carcinogen; EPA later classified it as unlikely to be a human carcinogen; federal court ruled it did not meet criteria to be a human carcinogen.
• B. EPA classified as carcinogen; IARC retracted; court ruled not a carcinogen.
• C. IARC classified as not a carcinogen; EPA classified as carcinogen; court overturned.
• D. Court found it carcinogenic; IARC never evaluated; EPA confirmed not a carcinogen.

Answer: (A)

In this situation, the sequence follows how different bodies approach cancer risk: first identify whether a substance could cause cancer (hazard), then assess the actual risk given exposure (risk assessment), and finally have a legal ruling about how the evidence supports labeling it as a carcinogen. IARC’s role is hazard identification—they label a substance as a probable carcinogen based on the strength of the evidence that it could cause cancer in humans, regardless of how much people are exposed. Glyphosate was labeled as a probable human carcinogen in that assessment, which signals a warning about the potential hazard. EPA then does a risk-based evaluation, looking at how people might be exposed and what the actual dose-response would imply for cancer risk. In this case, EPA concluded that glyphosate is unlikely to be a human carcinogen under typical exposure scenarios, which is a different kind of conclusion from IARC’s hazard label because it weighs exposure and real-world risk rather than hazard alone. A court’s role is to review whether the regulatory determination meets legal standards and uses the evidence appropriately. The court in this scenario ruled that glyphosate did not meet the criteria to be labeled a human carcinogen, despite IARC’s hazard classification. This shows the distinct functions of each body—the hazard signal from IARC, the regulatory risk assessment by EPA, and the legal standard applied by the court. Other sequences would imply either EPA’s risk conclusion preceded hazard identification or that court findings precede an agency’s assessment, which doesn’t align with how these processes operate or with the reported outcomes.

In this situation, the sequence follows how different bodies approach cancer risk: first identify whether a substance could cause cancer (hazard), then assess the actual risk given exposure (risk assessment), and finally have a legal ruling about how the evidence supports labeling it as a carcinogen. IARC’s role is hazard identification—they label a substance as a probable carcinogen based on the strength of the evidence that it could cause cancer in humans, regardless of how much people are exposed. Glyphosate was labeled as a probable human carcinogen in that assessment, which signals a warning about the potential hazard.

EPA then does a risk-based evaluation, looking at how people might be exposed and what the actual dose-response would imply for cancer risk. In this case, EPA concluded that glyphosate is unlikely to be a human carcinogen under typical exposure scenarios, which is a different kind of conclusion from IARC’s hazard label because it weighs exposure and real-world risk rather than hazard alone.

A court’s role is to review whether the regulatory determination meets legal standards and uses the evidence appropriately. The court in this scenario ruled that glyphosate did not meet the criteria to be labeled a human carcinogen, despite IARC’s hazard classification. This shows the distinct functions of each body—the hazard signal from IARC, the regulatory risk assessment by EPA, and the legal standard applied by the court.

Other sequences would imply either EPA’s risk conclusion preceded hazard identification or that court findings precede an agency’s assessment, which doesn’t align with how these processes operate or with the reported outcomes.